Celldex SVP granted 57,000 stock options

Celldex Therapeutics, Inc. reported that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options to buy common stock.

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options to buy common stock.

The options have an exercise price of $34.09 per share, were granted under the company’s 2021 Omnibus Equity Incentive Plan, and represent compensation rather than an open-market purchase.

According to the filing, 25% of the award will vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the options will expire on June 25, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 57,000 shares

Grant/Award 1 txn

Insider Young Diane C.

Role SVP, CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	57,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 57,000 contracts (Direct)

Footnotes (2)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. F2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Options granted: 57,000 options Exercise price: $34.09 per share Vesting cliff: 25% on June 25, 2027 +3 more

6 metrics

Options granted 57,000 options Incentive Stock Option grant to SVP CMO Diane C. Young

Exercise price $34.09 per share Strike price for the Incentive Stock Options

Vesting cliff 25% on June 25, 2027 Initial vesting date for the option award

Remainder vesting period 12 quarterly installments Remaining 75% vests over subsequent quarters

Option expiration June 25, 2036 Final date to exercise the options

Total derivative holdings after grant 57,000 options Total options reported following this transaction

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vesting, exercise price

4 terms

Incentive Stock Option financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

vesting financial

"25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 34.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex (CLDX) disclose in this Form 4 for Diane C. Young?

Celldex disclosed that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options. These options are part of her equity compensation and give her the right to purchase Celldex common stock at a set exercise price.

How many Celldex (CLDX) stock options were granted to Diane C. Young and at what price?

Diane C. Young was granted 57,000 Incentive Stock Options with an exercise price of $34.09 per share. This grant allows her to buy Celldex common stock at that fixed price once the options vest according to the schedule.

What is the vesting schedule for Diane C. Young’s Celldex (CLDX) stock options?

The options vest over several years: 25% of the award will vest on June 25, 2027. The remaining 75% will then vest in equal quarterly installments over the subsequent 12 quarters, creating a long-term incentive tied to continued service.

When do Diane C. Young’s Celldex (CLDX) stock options expire?

The granted stock options expire on June 25, 2036, if not exercised earlier. This expiration date defines the final day she can use the options to purchase Celldex common shares at the $34.09 exercise price, subject to vesting conditions.

Is this Celldex (CLDX) Form 4 an open-market purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market purchase. The filing identifies the transaction as a grant of Incentive Stock Options awarded under Celldex’s 2021 Omnibus Equity Incentive Plan, with no cash price paid at grant.

How many derivative securities does Diane C. Young hold after this Celldex (CLDX) transaction?

Following this transaction, Diane C. Young holds 57,000 derivative securities in the form of Incentive Stock Options. The Form 4 shows this as her total options position from this grant after the award was made, held directly in her name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Diane C.

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		57,000		06/25/2027(2)	06/25/2036	Common Stock	57,000	$0	57,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Diane C. Young	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)